<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Cancer Treatment Today &#187; Urology</title>
	<atom:link href="http://cancertreatmenttoday.org/category/professional-articles/urology/feed/" rel="self" type="application/rss+xml" />
	<link>http://cancertreatmenttoday.org</link>
	<description>Knowledge is Power</description>
	<lastBuildDate>Thu, 26 Mar 2026 23:39:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>TTMed Urology &#8211; pro</title>
		<link>http://cancertreatmenttoday.org/ttmed-urology-pro/</link>
		<comments>http://cancertreatmenttoday.org/ttmed-urology-pro/#comments</comments>
		<pubDate>Sat, 30 Jun 2012 13:44:38 +0000</pubDate>
		<dc:creator>M Levin, MD</dc:creator>
				<category><![CDATA[Professional]]></category>
		<category><![CDATA[Urology]]></category>

		<guid isPermaLink="false">http://cancertreatmenttoday.org/?page_id=1871</guid>
		<description><![CDATA[As medical websites appear and proliferate, the patient as well as a practitioner, face complex choices. Many sites claim to deliver accurate, reliable and up to date medical information and some do…but many do not. It is therefore refreshing to encounter a site that delivers what it promises. TTMed Urology is such a site. Chock-full [...]]]></description>
			<content:encoded><![CDATA[<p>As medical websites appear and proliferate, the patient as well as a practitioner, face complex choices. Many sites claim to deliver accurate, reliable and up to date medical information and some do…but many do not. It is therefore refreshing to encounter a site that delivers what it promises.</p>
<p>TTMed Urology is such a site. Chock-full of useful and high-quality information, it an invaluable resource for urology specialists and others interested in urology. The site covers common medical conditions and contains webcasts, articles, congress reports, expert interviews, news and events. An interesting and useful feature is “surgical video”, which sounds exactly like what it is, a visual guide to urological procedures. Teaching slides provide the touch of sophistication to that lecture of talk that you have coming up but do not have time to prepare. TTI Urology presents E-Prints, interesting articles from the current literature. The offerings are rounded out by “Ask the Expert” section, UroBlog, Multimedia Animations and other offerings. It is a professional and informative site that I can heartily recommend.</p>
]]></content:encoded>
			<wfw:commentRss>http://cancertreatmenttoday.org/ttmed-urology-pro/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Chemoradiation for Urethral Cancer &#8211; pro</title>
		<link>http://cancertreatmenttoday.org/chemoradiation-for-urethral-cancer-pro/</link>
		<comments>http://cancertreatmenttoday.org/chemoradiation-for-urethral-cancer-pro/#comments</comments>
		<pubDate>Sat, 30 Jun 2012 13:42:50 +0000</pubDate>
		<dc:creator>M Levin, MD</dc:creator>
				<category><![CDATA[Professional]]></category>
		<category><![CDATA[Urethral Cancer]]></category>
		<category><![CDATA[Urology]]></category>

		<guid isPermaLink="false">http://cancertreatmenttoday.org/?page_id=1867</guid>
		<description><![CDATA[Urethral cancer is very rare, encompassing less than 1% of all malignancies. There are less than 2000 cases in the literature. Optimal management, at present, is not defined and often relies on the limited experience gained from reestrospective study of individual cases and case series. Squamous histology is less common than transitional. Case reports suggest [...]]]></description>
			<content:encoded><![CDATA[<p>Urethral cancer is very rare, encompassing less than 1% of all malignancies. There are less than 2000 cases in the literature. Optimal management, at present, is not defined and often relies on the limited experience gained from reestrospective study of individual cases and case series. Squamous histology is less common than transitional. Case reports suggest that radiation and chemoradiation are more often used in women than men, in whom surgical treatment is more common.</p>
<p>Eng et al (2003 reported that the patients who survived the longest are ones who received combination therapy that consisted of either chemotherapy with radiation therapy or neoadjuvant chemotherapy with radiation therapy prior to surgery. Cohen in 2008 used 5FU and mitomycine as radiosensitizers.</p>
<p>Cohen MS, Triaca V, Billmeyer B, Hanley RS, Girshovich L, Shuster T, et al. Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra. J Urol. Feb 2008;179(2):536-41; discussion 541</p>
<p>Eng TY, Naguib M, Galang T, Fuller CD. Retrospective study of the treatment of urethral cancer. Am J Clin Oncol. Dec 2003;26(6):558-62.</p>
]]></content:encoded>
			<wfw:commentRss>http://cancertreatmenttoday.org/chemoradiation-for-urethral-cancer-pro/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
